PT  - JOURNAL ARTICLE
AU  - Jelena Mustra Rakic
AU  - Siyang Zeng
AU  - Linnea Rohdin-Bibby
AU  - Erin L Van Blarigan
AU  - Xingjian Liu
AU  - Shuren Ma
AU  - John P Kane
AU  - Rita Redberg
AU  - Gerard M. Turino
AU  - Eveline Oestreicher Stock
AU  - Mehrdad Arjomandi
TI  - Elastin degradation markers are elevated in never-smokers with past history of prolonged exposure to secondhand tobacco smoke and are inversely associated with their lung function
AID  - 10.1101/2021.12.11.21267498
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.11.21267498
4099  - http://medrxiv.org/content/early/2021/12/13/2021.12.11.21267498.short
4100  - http://medrxiv.org/content/early/2021/12/13/2021.12.11.21267498.full
AB  - Background Prolonged past exposure to secondhand tobacco smoke (SHS) in never-smokers is associated with occult obstructive lung disease and abnormal lung function, in particular reduced diffusing capacity. Previous studies have shown ongoing SHS exposure to be associated with increased elastin degradation markers (EDM) desmosine and isodesmosine.Research Question Are EDM levels elevated in persons with remote history of SHS exposure, and are those levels associated with reduced lung function?Study Design and Methods We measured the plasma levels of EDM from 193 never-smoking flight attendants with history of remote but prolonged SHS exposure in aircraft cabin and 103 nonsmoking flight attendants or sea-level control participants without history of cabin SHS exposure, and examined those levels versus their lung function with adjustment for covariates. The cabin SHS exposure was estimated based on airline employment history and dates of smoking ban enactment. EDM plasma levels were quantified by high-performance liquid chromatography and tandem mass spectrometry.Results The median [interquartile range; IQR] plasma EDM level for all participants was 0.30 [0.24 to 0.36] ng/mL with a total range of 0.16 to 0.65 ng/mL. Plasma EDM levels were elevated in those with history of exposure to cabin SHS compared to those not exposed (0.33±0.08 vs. 0.26±0.06 ng/mL; age- and sex-adjusted P<0.001). In those with history of cabin SHS-exposure, higher EDM levels were associated with lower diffusing capacity (parameter estimate (PE) [95%CI]=4.2 [0.4 to 8.0] %predicted decrease per 0.1 ng/mL increase in EDM; P=0.030). Furthermore, EDM levels were inversely associated with FEV1, FEV1/FVC, and FEF25-75 (PE [95%CI]=5.8 [2.1 to 9.4], 4.0 [2.2 to 5.7], and 12.5 [5.8 to 19.2]% predicted decrease per 0.1 ng/mL increase in EDM, respectively) (P<0.001).Interpretation Prolonged past exposure to SHS, even when remote, is associated with higher systemic elastin degradation markers that in turn is associated with lower lung function and in particular reduced diffusing capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by: 1.Flight Attendant Medical Research Institute (FAMRI) (012500WG and CIA190001 to MA; CIA150034 to GMT; FAMRI Center of Excellence Award#012500 to RR). 2.California Tobacco-Related Disease Research Program (TRDRP) (T29IR0715 to MA). 3.The Department of Veterans Affairs (CXV-00125 to MA). 4.National Library of Medicine Training Grant (NIH: T15LM007442 to SZ) 5.Postdoctoral Training in Tobacco Control Research (NIH/NCI: T32 CA113710 to JMR) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board (IRB) of the University of Rochester Medical Center (URMC), University of North Carolina (UNC), and University of California, San Francisco (UCSF) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.(CF)Cellulose fiber powders(COPD)Chronic obstructive pulmonary disease(D/I)Desmosine/isodesmosine(DCO)Diffusing capacity(FAs)Flight attendants(FAMRI)Flight attendant medical research institute(FEF)Forced expiratory flow(FEV1)Forced expiratory volume in 1 second(FVC)Forced vital capacity(SHS)Solid phase extraction(SPE)Secondhand smoke